STAT reports a small biotech reached an FDA breakthrough by agreeing to a clinical trial plan, but the agreement came four months too late, implying regulatory timing can materially affect development outcomes.
In February, a small biotech company reached a breakthrough with the FDA, agreeing to a clinical trial plan.
The problem: The agreement came four months too late.
This finding is one of many signals tracked across Healthcare. The live feed updates every few hours with new authority voices, debates, and emerging ideas.
← Back to Healthcare